# EARLY PHASE CLINICAL TRIAL TO EVALUATE ANTIVIRALS (APP)

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2022 · $6,142,134

## Abstract

To support a Phase I clinical trial to evaluate a promising new antiviral.  The drug is intended to be used in an outpatient setting, a key objective of the Antiviral Program for Pandemics funded by the American Rescue Plan.

## Key facts

- **NIH application ID:** 10710287
- **Project number:** 75N91019D00024-0-759102200017-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** THERESA ENGEL
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $6,142,134
- **Award type:** —
- **Project period:** 2022-09-19 → 2024-09-18

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10710287

## Citation

> US National Institutes of Health, RePORTER application 10710287, EARLY PHASE CLINICAL TRIAL TO EVALUATE ANTIVIRALS (APP) (75N91019D00024-0-759102200017-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10710287. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*